Mongoose Bio invited to Join Consortium to study T-cells on the International Space Station with the aim to Uncover Novel Cancer Targets
Mongoose teams up with global leaders, including NASA, to explore the effects of microgravity on T-Cells
Houston, Texas, July 31, 2024 – Mongoose Bio, a private clinical-stage biopharmaceutical company pioneering next generation precision T-cell based therapies targeting solid cancers, today announced that it has been invited to participate in a global consortium focused on studying the effects of microgravity on the human immune system, specifically human T-cells. The consortium brings together esteemed institutions and organizations, including The University of Texas, MD Anderson Cancer Center, Axiom Space, BioServe Space Technologies, and Deep Space Biology.
“We are thrilled to be part of such an elite group taking part in studies that could have profound effects on how we understand and potentially treat cancer here on earth,” said Neil Warma, President and CEO of Mongoose Bio. “One of the goals for this mission will be to send human T-cells, the body’s frontline immune defenders, into space for experiments aboard the International Space Station (ISS). By subjecting these immune cells to the unique conditions of microgravity, the group of researchers hopes to uncover novel signaling pathways and identify potential immune targets. The role of Mongoose Bio, specifically, is to translate these findings from the cosmic laboratory to clinical development and ideally commercialization. As part of this collaboration, we are aiming to develop new therapies that harness the insights gained from this interstellar endeavor to create new treatments for cancer on earth.”
“We are excited to join with talented collaborators who are experienced in biological research and in delivering payloads to deep space in order to leverage the unique research environment of sustained microgravity on the ISS National Laboratory,” said Cassian Yee, MD, professor of Melanoma Medical Oncology at the MD Anderson Cancer Center and Scientific Founder of Mongoose Bio. “We look forward to this opportunity to study how T cells are affected by microgravity, identify novel targets and translate these findings into meaningful therapeutic strategies that can improve cellular therapies and enhance life here on Earth.”
This project is supported by a grant awarded by the Center for the Advancement of Science in Space, Inc. (CASIS), which manages the ISS National Laboratory. CASIS and the Biological and Physical Sciences division of the National Aeronautics and Space Administration (NASA) intend to select and fund spaceflight projects that lead to defined milestones in technological innovation that are in alignment with national research and technology development priorities and with the ISS National Lab mission to benefit humanity and the U.S. economy.
About Mongoose Bio, Inc.
Mongoose Bio is a clinical-stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for solid cancers. Mongoose Bio combines a combination of proprietary methodologies including a Immunopeptidome Discovery Platform (IDP) and Epigenetic T Cell Reprogramming (ECMR) to develop next-generation adoptive TCR-T cell therapies. More information can be found at www.mongoosebio.com
Forward Looking Statements
This press release contains forward-looking statements, which are subject to risks and uncertainties. These statements reflect the company’s current expectations regarding future events, including, but not limited to clinical development timelines, regulatory approvals, and commercial potential. Actual results could differ materially due to factors such as scientific, clinical, operational, or financial challenges. The company undertakes no obligation to update these statements except as required by law.
Investor Relation & Media Contact:
Email: info@mongoosebio.com